| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 207.6 | 191.8 |
| Gross profit | 99.6 | 98.6 |
| Profit before tax | 49.1 | 21.5 |
| Net income | 37.8 | 17.4 |
| EPS (diluted, $ a share) | $0.87 | $0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +117.7% |
|---|---|
| Revenue, year on year | +8.2% |
| Gross margin | 48.0% |
| Operating margin | 24.5% |
10-Q filed with the SEC, NASDAQ: AMPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Amphastar Pharmaceuticals, Inc.: key numbers
- Share price
- $29.17Close, Nov 16
- Market cap
- $1.24B
- Shares outstanding
- 42.65MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Amphastar Pharmaceuticals, Inc.
All →Amphastar Pharmaceuticals Financial Results
Amphastar Pharmaceuticals reported third quarter 2026 net revenues of $207.6 million, an 8% increase year-over-year driven by record sales of BAQSIMI and Primatene MIST. The company achieved GAAP net income of $37.8 million, or $0.87 per diluted share, significantly up from $17.4 million in the prior year period.
- Term
- 3 months
“Our third quarter results demonstrate the strength of Amphastar’s diversified portfolio and the commercial platform we have built. Record sales of BAQSIMI® and Primatene MIST®, together with contributions from recently launched products, supported continued revenue growth and further strengthened the foundation for our long-term strategy.”
Dr. Jack Zhang, Amphastar’s President and Chief Executive Officer